

---

## BIOCAPTIVA Appoints Alison Williamson as Chief Financial Officer and Board Director



---

BIOCAPTIVA Ltd, a company developing the BioCaptis, a revolutionary cell free DNA (cfDNA) capture device, designed to transform liquid biopsy testing for cancer management, announces the appointment of Alison Williamson as Chief Financial Officer and member of the Board.

Alison is a highly accomplished senior finance professional with over 30 years' experience in financial strategy, M&A, business planning, risk management and financial modelling. Prior to joining BIOCAPTIVA, Alison was CFO at DYSIS Medical Ltd, a global medical device business developing cancer screening technologies.

Previously, Alison was Finance Director at Aircraft Medical, a specialist manufacturer of video laryngoscopes used for challenging intubations, initially in a part time capacity before joining the company full time in 2010, before it was acquired for \$110 million in cash by the leading global medtech company, Medtronic.

Alison began her career at KPMG where she qualified as a chartered accountant in 1988. Since then, Alison has held a number of roles in tax and corporate finance at accountancy firms RMD and Deloitte.

**Jeremy Wheeler, CEO of BIOCAPTIVA, said,** "I am delighted to welcome Alison to the Board and senior team at BIOCAPTIVA. Alison has a strong track record of fund raising and successful exits through her career in medtech which will be hugely important as we enter our next growth phase. As we look to start the first in human trial with the BioCaptis, Alison's commercial awareness and operational expertise will be critical in supporting the path ahead for the company.

"BIOCAPTIVA has made significant progress since spinning out of the University of Edinburgh just over a year ago. I am confident that the company, with the valuable addition of Alison to the team, will continue to forge ahead as we have demonstrated in our first year of operations."

**Alison Williamson added,** "I am thrilled to join BIOCAPTIVA, a company whose technology is poised to truly revolutionise the liquid biopsy market. BIOCAPTIVA is at a very exciting stage of development, and I look forward to working alongside Jeremy and the team at BIOCAPTIVA to ensure its future success."

**Source:** [BIOCAPTIVA](#)

Published on : Wed, 13 Apr 2022